Small intestinal bacterial overgrowth (SIBO) is a measurable clinical disorder defined by excessive bacteria in the small intestine, whereas leaky gut is an unvalidated diagnostic label for increased intestinal permeability. At Longevity Benchmark, we evaluate clinical diagnostics and functional gut panels against published gastroenterology guidelines to help readers prioritize tests that yield actionable medical results. When chronic bloating, abdominal pain, and bowel changes appear, patients frequently encounter both terms alongside irritable bowel syndrome (IBS) and coeliac disease.
The Verdict
The Four Gut Conditions Defined by Mechanism, Syndrome, and Disease
Understanding the distinction between a physiological mechanism, a functional syndrome, and an autoimmune disease prevents misdirected diagnostic testing. Increased intestinal permeability, commonly termed leaky gut, refers to a proposed mechanism where the barrier function of the small intestinal epithelium becomes impaired, allowing luminal antigens into systemic circulation. In a 2024 review published in Gastroenterology & Hepatology, Lacy, Wise, and Cangemi noted that leaky gut syndrome is not currently accepted as a formal medical diagnosis, because no validated tool exists to accurately diagnose it in clinical practice.
Small intestinal bacterial overgrowth (SIBO) is a defined clinical condition characterized by an abnormally high bacterial population in the small intestine. According to the 2020 American College of Gastroenterology (ACG) clinical guideline, SIBO is defined by a bacterial colony count of at least 10^3 colony-forming units per millilitre (CFU/mL) on duodenal aspirate culture. The excess bacteria ferment carbohydrates into hydrogen gas, while methanogenic archaea produce methane, leading to malabsorption, nutritional deficiencies, and gas-related symptoms.
Irritable bowel syndrome (IBS) is a functional disorder of gut-brain interaction characterized by recurrent abdominal pain linked to bowel movements, defined formally by the Rome IV diagnostic criteria. In contrast, coeliac disease is a serious autoimmune disease affecting approximately 1% of the population in Europe and the United States, triggered by dietary gluten in genetically predisposed individuals. While coeliac disease causes demonstrable duodenal villous atrophy that resolves strictly on a gluten-free diet, IBS involves altered visceral sensitivity and motility without structural enterocyte loss.
Diagnostic Validity and Testing Methods Across Conditions
Objective diagnostic testing separates validated medical disorders from proposed physiological mechanisms. Coeliac disease and SIBO rely on validated laboratory and physiological markers, whereas commercial leaky gut testing lacks diagnostic validation.
| Condition | Clinical Category | Diagnostic Method | Validated Reference Standard | Diagnostic Status |
|---|---|---|---|---|
| Coeliac Disease | Autoimmune disease | Tissue transglutaminase IgA (tTG-IgA) serology followed by duodenal biopsy | Duodenal mucosal histopathology showing villous atrophy (Marsh classification) | Fully established medical diagnosis |
| SIBO | Bacterial overgrowth disorder | Glucose or lactulose breath testing (hydrogen and methane) | Quantitative small bowel aspirate culture (≥10^3 CFU/mL) | Established clinical diagnosis with recognized breath testing limitations |
| Irritable Bowel Syndrome (IBS) | Disorder of gut-brain interaction | Clinical evaluation using Rome IV symptom criteria and targeted negative baseline blood markers | Rome IV symptom criteria | Established clinical syndrome via positive diagnostic strategy |
| Leaky Gut Syndrome | Proposed physiological mechanism | Unregulated commercial assays (such as serum zonulin or lactulose-mannitol ratios) | None; no validated clinical diagnostic reference standard exists | Unrecognized as an independent medical diagnosis |
Overlapping Symptoms and Distinguishing Clinical Features
Abdominal bloating, distension, and altered bowel habits occur across all four conditions, making symptom presentation alone inadequate for distinguishing between them. Patients presenting with chronic digestive distress frequently report identical daily complaints whether their underlying driver is microbial fermentation, mucosal inflammation, or neurogastroenterological hypersensitivity.
Specific distinguishing markers and systemic complications help clinicians separate these presentations. Malabsorption leading to iron deficiency anaemia, unexplained weight loss, and duodenal villous blunting points toward mucosal damage such as coeliac disease. In contrast, excessive postprandial gaseous distension occurring within 90 minutes of carbohydrate consumption frequently characterizes bacterial fermentation in the upper intestine.
| Clinical Feature | Leaky Gut Claims | SIBO | IBS | Coeliac Disease |
|---|---|---|---|---|
| Abdominal Bloating | Frequently attributed in commercial marketing | Predominant symptom driven by bacterial gas production | Commonly reported in over 70% of individuals | Common secondary presentation due to malabsorption |
| Altered Bowel Habits | Diarrhoea or constipation claimed inconsistently | Diarrhoea typical with hydrogen; constipation associated with methane | Core diagnostic requirement (diarrhoea, constipation, or mixed) | Chronic diarrhoea common, though constipation occurs |
| Abdominal Pain | Non-specific discomfort reported | Frequent, related to gaseous bowel distension | Obligate diagnostic requirement under Rome IV | Variable; often associated with nutrient ingestion |
| Nutritional Deficiencies | Broadly claimed without specific clinical markers | Fat-soluble vitamin and B12 deficiencies in severe overgrowth | Uncommon in uncomplicated presentations | Common (iron deficiency anaemia, folate, calcium, vitamin D) |
| Validated Biomarker | None available in routine clinical care | Breath hydrogen rise ≥20 ppm; breath methane ≥10 ppm | None; positive diagnosis based on symptom criteria | Elevated tTG-IgA serology; Marsh III duodenal histology |
SIBO Breath Testing Protocols and Interpretive Limits
Breath testing is the primary non-invasive method for evaluating SIBO, and published guidelines report wide variation in how well it performs. Per the 2017 North American Consensus criteria adopted in the 2020 ACG guideline, a rise in exhaled hydrogen of at least 20 parts per million (ppm) above baseline within 90 minutes of ingesting 75 grams of glucose or 10 grams of lactulose is considered diagnostic for SIBO. In practical testing protocols, carbohydrate doses vary between 75 grams and 100 grams for glucose, and 10 grams for lactulose.
The guidelines establish specific criteria for methane production. The 2020 ACG guideline states that a methane concentration of 10 ppm or greater at any point during testing indicates colonization by methanogenic archaea, specifically Methanobrevibacter smithii. Because archaea are not bacteria, the guideline notes that intestinal methanogen overgrowth (IMO) is a more accurate physiological term than SIBO for this presentation. Ghoshal (2011) observed that approximately 15% to 30% of individuals harbour methanogens that convert 4 atoms of hydrogen into 1 molecule of methane, meaning a hydrogen-only breath test can yield a false-negative result in these patients.
Diagnostic performance varies widely across clinical literature. In systematic reviews cited by the ACG guideline, lactulose breath test sensitivity ranged from 31% to 68% and specificity from 44% to 100%, while glucose breath testing demonstrated sensitivity from 20% to 93% and specificity from 30% to 86% against small bowel aspirate cultures. A refined lactulose breath test study reported 77% sensitivity and 88% specificity among SIBO-predisposed patients, but sensitivity dropped to 39% when applied across general IBS populations. Rapid small-bowel transit complicates interpretation: while the consensus assumes transit exceeds 90 minutes, healthy control scintigraphy demonstrates an average orocecal transit time of 85 to 91 minutes, and Ghoshal documented median transit times of 65 minutes in specific cohorts. When lactulose reaches the caecum prematurely, normal colonic fermentation creates an early hydrogen rise that mimics small-intestinal overgrowth.
Mail-in home breath testing kits present additional quality variables. While kits use laboratories certified under Clinical Laboratory Improvement Amendments (CLIA) standards, the 2020 ACG guideline cautions that pre-test dietary preparations, substrate ingestion timing, and sample collection occur in an unmonitored home environment that may introduce technical error.
The Clinical Imperative of Testing for Coeliac Disease First
Gastroenterology guidelines mandate screening for coeliac disease before initiating empirical treatments for functional bowel disorders or bacterial overgrowth. Coeliac disease triggers systemic immune activation and progressive enterocyte destruction, presenting with symptoms that completely mimic IBS, SIBO, and perceived leaky gut. Ruling it out early matters because coeliac disease is treatable and because the test stops working once gluten is removed from the diet.
First-line screening relies on tissue transglutaminase immunoglobulin A (tTG-IgA) testing alongside total serum IgA to identify selective IgA deficiency. In the 2016 Agency for Healthcare Research and Quality (AHRQ) Comparative Effectiveness Review, IgA tTG demonstrated a sensitivity of 92.6% (95% CI 90.2 to 94.5%) and a specificity of 97.6% (95% CI 96.3 to 98.5%). However, a verification-bias correction published by Hujoel and colleagues revised tTG-IgA sensitivity to 57.1% (95% CI 35.4 to 76.4%) while specificity remained 99.6% (95% CI 98.4 to 99.9%). If clinical suspicion remains high despite negative serology, small bowel duodenal biopsy during endoscopy remains necessary.
Importantly, several clinical conditions can mimic the duodenal histology seen in coeliac disease. The ACG celiac guideline lists small-bowel bacterial overgrowth, tropical sprue, autoimmune enteropathy, drug-associated enteropathy (such as olmesartan), Whipple disease, Crohn's disease, eosinophilic enteritis, intestinal lymphoma, giardiasis, graft versus host disease, and malnutrition as alternative causes of duodenal villous atrophy.
Irritable Bowel Syndrome as a Defined Clinical Diagnosis
Current medical guidelines classify irritable bowel syndrome as a positive diagnosis based on validated symptom criteria rather than an exclusionary diagnosis reached after exhaustive negative testing. The Rome IV consensus defines IBS as recurrent abdominal pain occurring on average at least one day per week over the previous three months, associated with two or more specific features: related to defaecation, associated with a change in stool frequency, or associated with a change in stool form. Symptoms must be fulfilled for the last three months with initial onset occurring at least six months prior to diagnosis.
The shift from Rome III to Rome IV substantially altered diagnostic epidemiology. Under Rome III, patients qualified based on abdominal discomfort alone, whereas Rome IV strictly requires abdominal pain. In the 2021 British Society of Gastroenterology (BSG) guideline, data from the Rome Foundation global survey across 73,000 adults showed worldwide IBS prevalence fell from 10.1% under Rome III to 4.1% under Rome IV. Meta-analytic data confirmed a pooled global prevalence of 3.8% under Rome IV compared to 9.2% under Rome III. Prevalence remains higher in women, with odds ratios of 1.46 to 1.8 across international cohorts, and peaks among adults aged 18 to 39 years.
Modern gastroenterology reclassified IBS from a functional disorder to a disorder of gut-brain interaction. The ACG guideline strongly recommends establishing a positive diagnosis using Rome criteria while avoiding non-targeted laboratory investigations. Specifically, the guideline recommends against routine food allergy and food sensitivity testing in IBS patients in the absence of reproducible physiological symptoms of an IgE-mediated allergy. Instead, clinical focus centres on managing visceral hypersensitivity, altered gut motility, and secondary microbial imbalances.
Overlap Rates and Diagnostic Interplay Between SIBO and IBS
A substantial proportion of individuals diagnosed with irritable bowel syndrome test positive for small intestinal bacterial overgrowth on breath testing. The 2020 ACG guideline highlights that while the exact rate remains actively debated, meta-analyses suggest that up to 78% of IBS patients test positive for SIBO. An independent study evaluating a refined lactulose breath test reported that 39% of IBS patients met SIBO diagnostic criteria, situating the finding within a broader published literature range of 30% to 85%.
Whether bacterial overgrowth represents the primary cause of IBS symptoms or an incidental downstream consequence of underlying dysmotility remains unsettled. Normal small intestinal clearance depends on phase III of the migrating motor complex, which sweeps residual food and microbes into the colon during fasting. Impairment of this clearance mechanism through scleroderma, autonomic neuropathy in diabetes, prior surgical blind loops, or medication use (including opioids and anticholinergics) permits colonic bacteria to migrate into and colonize the small bowel.
In 2015, the US Food and Drug Administration (FDA) approved the non-absorbable antibiotic rifaximin for IBS with diarrhoea, which reduces bacterial burden in the small intestine. However, the ACG guideline cautions that evidence remains insufficient to recommend routine probiotic administration for SIBO treatment, and notes there is currently no clinical basis for using fecal microbiota transplant (FMT) to manage small intestinal bacterial overgrowth.
Recommended Step-by-Step Sequence of Medical Investigation
Following a structured diagnostic sequence ensures serious, treatable conditions are identified before functional labels or mechanisms are considered. The BSG guideline outlines a direct testing pathway designed to confirm positive diagnoses while minimising unnecessary and unvalidated procedures.
- Step 1: Clinical History and Red-Flag Triage. A clinician reviews gastrointestinal symptoms and screens for the published alarm features, which carry different age thresholds for different symptoms and are listed in full in our guide to leaky gut symptoms. The presence of alarm features warrants immediate specialist endoscopic referral.
- Step 2: Objective Baseline Blood and Stool Markers. Initial laboratory workup includes a full blood count (FBC) to evaluate for anaemia, inflammatory markers including C-reactive protein (CRP) or erythrocyte sedimentation rate (ESR), and coeliac serology via tTG-IgA while on a gluten-containing diet. For individuals presenting with chronic loose stools, faecal calprotectin testing differentiates inflammatory bowel disease from functional disorders.
- Step 3: Positive Diagnosis of Irritable Bowel Syndrome. If baseline inflammatory and serological blood markers return normal, a clinician evaluates symptoms against the Rome IV criteria. In the absence of alarm features, meeting these criteria confirms a positive diagnosis of IBS without requiring routine colonoscopy or unvalidated food allergy panels.
- Step 4: Evaluation for SIBO or Intestinal Methanogen Overgrowth. For patients with persistent severe abdominal bloating, postprandial distension, or refractory diarrhoea, a clinician may order a standardized glucose or lactulose breath test. Elevating hydrogen by 20 ppm or methane by 10 ppm identifies bacterial overgrowth or IMO, which guides targeted antimicrobial therapy.
- Step 5: Contextualizing Intestinal Permeability. Intestinal permeability, or leaky gut, represents a physiological mechanism rather than an actionable clinical test. Because Lacy and colleagues (2024) confirmed that no validated diagnostic tool exists for leaky gut syndrome, commercial stool zonulin or permeability panels should be avoided in clinical decision-making.
Where Intestinal Permeability Fits in Clinical Practice
Intestinal permeability functions as a measurable physiological process in research laboratories, not as an independent clinical diagnosis to pursue with commercial test kits. Increased barrier permeability has been documented in established medical conditions including coeliac disease, inflammatory bowel disease, and post-infectious bowel disorders, reflecting ongoing mucosal inflammation or epithelial disruption.
This distinction dictates which patient populations benefit from clinical evaluation. This investigation pathway is not appropriate for individuals experiencing acute gastrointestinal infections, severe unexplained weight loss, gastrointestinal haemorrhage, or persistent vomiting, who require immediate medical attention. Furthermore, self-ordering consumer permeability assays is not recommended for general wellness monitoring, as results provide no validated diagnostic cutoff or established treatment guideline.
Our assessment of diagnostic value would change if prospective clinical trials validate a standardized, reproducible permeability assay that accurately predicts treatment response independently of underlying diagnoses like coeliac disease or IBD. If you are experiencing persistent digestive symptoms, bring your symptom diary to a licensed gastroenterologist to run baseline blood panels, screen for coeliac disease while consuming gluten, and discuss whether breath testing for SIBO is clinically indicated.
Frequently Asked Questions
Is leaky gut the same as SIBO?
No, leaky gut and SIBO are completely different concepts. Small intestinal bacterial overgrowth (SIBO) is an established medical disorder where bacteria abnormally colonize the small intestine, defined by bacterial counts of at least 10^3 CFU/mL on duodenal culture or a 20 ppm hydrogen rise on a breath test. Leaky gut is a popular term for increased intestinal permeability, which describes a biological mechanism where tight junctions between intestinal epithelial cells allow luminal contents into tissue. SIBO is an identifiable condition affecting bacterial distribution and gas production, whereas leaky gut is a proposed physiological mechanism that lacks formal status as a medical diagnosis.
Can you have SIBO and leaky gut at the same time?
Yes, bacterial overgrowth and increased intestinal permeability can coexist, but one is a clinical disorder and the other is a physiological state. When bacteria abnormally proliferate in the small intestine, microbial metabolites, bacterial toxins, and localized inflammation can disturb the mucosal lining and potentially alter epithelial permeability. However, increased permeability is not unique to SIBO and appears in established diseases such as coeliac disease and Crohn's disease. While clinicians can diagnose and treat SIBO using breath testing and targeted antibiotics, there is no validated diagnostic test to confirm whether secondary intestinal permeability is present.
What is the difference between leaky gut and IBS?
Irritable bowel syndrome (IBS) is a recognized disorder of gut-brain interaction diagnosed using the validated Rome IV symptom criteria, requiring recurrent abdominal pain at least one day per week associated with defecation or stool changes. Leaky gut refers to increased intestinal permeability, which is a cellular mechanism rather than a functional clinical diagnosis. While some research suggests that a subset of patients with IBS may exhibit altered barrier function, IBS is diagnosed through positive clinical criteria without needing permeability testing. Leaky gut lacks validated diagnostic criteria, reference standards, and accepted medical treatments.
How is SIBO diagnosed?
SIBO is diagnosed using hydrogen and methane breath testing or quantitative small bowel aspirate culture during endoscopy. Per the 2020 American College of Gastroenterology guideline, a culture yielding at least 10^3 colony-forming units per millilitre (CFU/mL) of bacteria in duodenal fluid is considered diagnostic. Non-invasive breath testing involves drinking a glucose or lactulose solution; a rise in exhaled hydrogen of at least 20 parts per million (ppm) above baseline within 90 minutes indicates SIBO. A methane level of 10 ppm or higher at any point during testing indicates intestinal methanogen overgrowth (IMO).
How is coeliac disease diagnosed?
Coeliac disease is diagnosed through initial serological blood testing followed by confirmatory duodenal biopsy while the patient is consuming gluten. The primary screening test is tissue transglutaminase immunoglobulin A (tTG-IgA), paired with total serum IgA to rule out selective IgA deficiency. If antibody levels are elevated, or if clinical suspicion is high, an upper endoscopy is performed to collect multiple biopsies from the duodenum to check for villous atrophy and mucosal blunting. Both blood tests and endoscopic biopsies must be conducted before eliminating gluten from your diet to prevent false-negative findings.
Which should I test for first?
You should test for coeliac disease before investigating SIBO or considering intestinal permeability. Coeliac disease is a serious, treatable autoimmune disease affecting roughly 1% of the population that causes progressive mucosal damage and nutrient malabsorption if left unmanaged. Establishing whether coeliac disease is present requires only routine serological blood testing, which must be performed before removing gluten. Once coeliac disease and systemic inflammation are excluded via baseline blood and stool tests, clinicians can evaluate symptoms for IBS or proceed to SIBO breath testing.
Do I need to be eating gluten before a coeliac test?
Yes, you must be eating gluten regularly for coeliac disease testing to be accurate. The blood test detects antibodies produced by the immune system in response to dietary gluten, and the endoscopic biopsy checks for mucosal damage caused by ongoing gluten consumption. If you eliminate gluten before testing, circulating antibody levels drop and the intestinal lining begins to heal, leading to false-negative results. In clinical challenge studies, a two-week gluten challenge resulted in false-negative findings in approximately 10% of patients, underscoring the need to remain on gluten until testing finishes.
Can SIBO cause intestinal permeability?
SIBO is hypothesized to contribute to increased intestinal permeability, but evidence remains associative rather than definitive. When large colonies of bacteria occupy the small intestine, bacterial fermentation, deconjugated bile acids, and lipopolysaccharides can stress the mucosal barrier and disrupt intercellular tight junctions. In clinical research, small-bowel bacterial overgrowth is documented alongside duodenal villous changes and barrier alterations. However, gastroenterology consensus does not recognize leaky gut as an independent downstream diagnosis, and treatment protocols focus directly on resolving bacterial overgrowth rather than targeting permeability independently.
Related
- Is Leaky Gut Real? Clinical Evidence and Institutional Perspectives
- Leaky Gut Tests: Diagnostic Accuracy and Validated Alternatives
- Leaky Gut Symptoms vs Look-Alike Digestive Disorders
- How Doctors Test Gut Health: From Serology to Endoscopy
- Elevated Calprotectin Causes and Clinical Interpretation
- Doctor-Led Digestive Health and Longevity Programs